Correlation between Helicobacter pylori infection and pulmonary wegener's granulomatosis activity

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 6, 2008, Pages 845-851

  Zycinska, K ^a   Wardyn, K A ^a   Zycinski, Z ^a   Smolarczyk, R ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Helicobacter pylori; Infection; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GASTROINTESTINAL AGENT; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; NAPROXEN; PREDNISONE; PROTON PUMP INHIBITOR; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GASTRODUODENAL ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; PREVALENCE; SINGLE DRUG DOSE; TREATMENT DURATION; WEGENER GRANULOMATOSIS; DUODENUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; MIDDLE AGED; PATHOLOGY; STOMACH;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DUODENUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; STOMACH; WEGENER GRANULOMATOSIS;

EID: 64549157161     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Zycinska K, Wardyn KA, Zielonka TM, Otto M. The role of ANCA and anti-GBM antibodies in pulmonary-renal syndrom due to Wegener's granulomatosis. J Physiol Pharmacol 2007; 58 Suppl 5: 839-846.
2. Pagnoux C, Teixeira L. Wegener's Granulomatosis. Presse Med 2007; 36: 860-874.
3. Langford CA. Vasculitis in the geriatric population. Rheum Dis Clin North Am 2007; 33: 177-195.
4. Taha AS, Sturrock RD, Russell RI. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine and nonsteroidal anti-inflammatory drugs. Am J Gastroenterology 1992; 87: 1732-1735. 5. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterology 1998; 93: 1800-1802.
5. Apan TZ, Görsel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin- associated gene-A in Behçet's disease. Clin Rheumatol 2007; 26: 885-889.
6. Gasbarrini A, Carloni E, Gasbarrini G, Chisholm SA. Helicobacter pylori and extragastric diseases-other Helicobacters. Helicobacter 2004; 9 Suppl 1: 57-66.
7. Novak J, Szekenecz Z, Sebesi J et al. Elevated levels of anti-Helicobacter pylori antibodies in Henoch-Schönlein purpura. Autoimmunity2003; 36: 307-311.
8. de Leest HTJI, Steen KSS, van Wijngaarden S, Lems WF, van der Laar MAFJ, Dijkmans BAC. The prevalence of Helicobacter pylori is still substantial in rheumatic patients. Scan J Rheumatology 2002; 31: 94-96.
9. Ishikawa N, Fuchigami T, Matsumoto T et al. Helicobacter pylori infection in rheumatoid arthritis: effect of drugs on prevalence and correlation with gastroduodenal lesion. Rheumatology 2002; 41: 72-77.
10. Zentilin P, Savarino V, Garnero A, Accardo S, Seriolo B. Is Helicobacter pylori infection a risk factor for disease severity in rheumatoid arthritis? Gastroenterology 1999; 116: 503-504.
11. Mizokami Y, Tamura K, Fukada Y, Yamamoto I, Shimoyama T. Non-steroidal anti- inflammatory drugs associated with gastroduodenal injury and Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6 (Supp 1): 109-112.
12. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352: 330-333.
13. Nikkari S, Relman DA. Molecular approaches for identification of infectious agents in Wegener's granulomatosis and other vasculitides. Curr Opin Rheumatol 1999; 11: 11-16.
14. Guilpain P, Guillevin L, Mouthon L. New insights into pathogenesis of ANCA-associated vasculitides. Presse Med 2007; 36: 854-859.
15. Egermayer P. The role of infectious agents in pulmonary and systemic vascular disease. Expert Opin Pharmacother 2001; 2: 1093-1097.
16. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155-168.
17. van Zanten SV, van der Knoop B. Gastric ulcer treatment: cure of Helicobacter pylori infection without subsequent acid-suppressive therapy: is it effective? Eur J Gastroenterol Hepatol 2008; 20: 489-491.
18. Robinson K, Kenefeck R, Pidgeon E et al. Helicobacter pylori-induced peptic ulcer disease in associated with inadequate regulatory T-cell responses. Gut 2008; 57: 1375-1385.
19. Umit H, Tezel A, Bukavaz S. The relationship between virulence factors of Helicobacter pylori and severity of gastritis in infected patients. Dig Dis Sci 2008 May 9 (Epub ahead of print).